Trevi Therapeutics director granted 35,000 stock options
Trevi Therapeutics director Anne Vanlent received a grant of stock options covering 35,000 shares of common stock.
Rhea-AI Filing Summary
Trevi Therapeutics director Anne Vanlent received a grant of stock options covering 35,000 shares of common stock. The nonstatutory options have an exercise price of $13.45 per share and expire on June 2, 2036. All 35,000 underlying shares are scheduled to fully vest on the earlier of the first anniversary of the June 3, 2026 grant date or the next annual meeting of stockholders, as long as she continues serving as a director, employee or consultant. Following this award, her reported derivative holdings from this grant total 35,000 options, reflecting a routine compensation-related acquisition rather than an open-market purchase.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 35,000 shares
Grant/Award
1 txn
Insider
VANLENT ANNE
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Nonstatutory Stock Option (right to buy) | 35,000 | $0.00 | $0.00 |
Holdings After Transaction:
Nonstatutory Stock Option (right to buy) — 35,000 contracts (Direct)
Footnotes (1)
- F1. This option was granted on June 3, 2026. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer.
Key Figures
Option grant size: 35,000 shares
Exercise price: $13.45 per share
Expiration date: June 2, 2036
+2 more
5 metrics
Option grant size
35,000 shares
Nonstatutory stock option covering common stock
Exercise price
$13.45 per share
Exercise price of nonstatutory stock option
Expiration date
June 2, 2036
Option expiration for 35,000-share grant
Shares underlying options
35,000 shares
Underlying common stock for granted options
Shares following transaction
35,000 derivative shares
Total options held from this grant after award
Key Terms
Nonstatutory Stock Option, exercise price, expiration date, annual meeting of stockholders, +1 more
5 terms
Nonstatutory Stock Option financial
"Nonstatutory Stock Option (right to buy)"
A nonstatutory stock option (also called a non-qualified stock option) is an employee or contractor right to buy company shares at a set price that does not qualify for special tax treatment. When exercised, the difference between the market price and the set price is treated as ordinary income for the recipient and usually triggers payroll tax and withholding. For investors, these options matter because they create potential share dilution, affect reported compensation costs, and influence the timing of when new shares enter the market—similar to a coupon that lets someone buy stock at a discount but results in an immediate tax bill.
exercise price financial
"conversion_or_exercise_price": "13.4500""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date": "2036-06-02T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
annual meeting of stockholders financial
"the date of the next annual meeting of stockholders of the Issuer"
grant, award, or other acquisition financial
"transaction_code_description": "Grant, award, or other acquisition""
FAQ
What did Trevi Therapeutics (TRVI) director Anne Vanlent report on this Form 4?
Anne Vanlent reported receiving a grant of stock options for 35,000 shares of Trevi Therapeutics common stock as director compensation, with a set exercise price and future vesting conditions tied to continued service.
What is the exercise price of Anne Vanlent’s Trevi Therapeutics (TRVI) options?
The granted options have an exercise price of $13.45 per share. This means she can purchase Trevi Therapeutics common stock at $13.45 once the options vest and before they expire in 2036.
When do the new Trevi Therapeutics (TRVI) stock options vest for the director?
The options are scheduled to fully vest on the earlier of one year after the June 3, 2026 grant date or the next annual stockholder meeting, provided Anne Vanlent continues serving as a director, employee or consultant.
When do Anne Vanlent’s Trevi Therapeutics (TRVI) stock options expire?
The granted options expire on June 2, 2036. She must exercise any vested options before this expiration date or they will lapse, consistent with typical long-term equity compensation structures.
AI-generated analysis. How Rhea-AI works. Not financial advice.
